ArticleMolecular cancer therapeutics2009

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer.

Jen Jen Yeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.